ConductScience.org, home

Paper41008338

Immunological Targets in Generalized Myasthenia Gravis Treatment: Where Are We Going Now?

Rossini E and 4 others. Brain Sci, 2025. Cited by 5 papers, by iCite.

Cite this record

ConductScience Library. Immunological Targets in Generalized Myasthenia Gravis Treatment: Where Are We Going Now? Papers, record 41008338. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41008338

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Immunological Targets in Generalized Myasthenia Gravis Treatment: Where Are We Going Now?
PubMed
Journal
Brain Sci
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
5
iCite
Relative citation ratio, by iCite
1.33, provisional
iCite
Revised in PubMed
2025-09-30
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Rossini EElenahttps://orcid.org/0009-0002-7862-6743
2Leonardi LLuca
3Morino SStefania
4Antonini GGiovanni
5Fionda LLaurahttps://orcid.org/0000-0002-8813-2272

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References170

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
124373505A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis.J Autoimmun2014https://conductscience.org/library/papers/24373505PubMed
238751755Effectiveness and safety of telitacicept for refractory generalized myasthenia gravis: a retrospective study.Ther Adv Neurol Disord2024https://conductscience.org/library/papers/38751755PubMed
339987373Myasthenia gravis in 2025: five new things and four hopes for the future.J Neurol2025https://conductscience.org/library/papers/39987373PubMed
432526271Circulating Th1/17 cells serve as a biomarker of disease severity and a target for early intervention in AChR-MG patients.Clin Immunol2020https://conductscience.org/library/papers/32526271PubMed
523341732New treatments for myasthenia: a focus on antisense oligonucleotides.Drug Des Devel Ther2013https://conductscience.org/library/papers/23341732PubMed
627220659International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r.Muscle Nerve2016https://conductscience.org/library/papers/27220659PubMed
712360217Unravelling the pathogenesis of myasthenia gravis.Nat Rev Immunol2002https://conductscience.org/library/papers/12360217PubMed
838436998Batoclimab vs Placebo for Generalized Myasthenia Gravis: A Randomized Clinical Trial.JAMA Neurol2024https://conductscience.org/library/papers/38436998PubMed
935639288Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals.Drugs2022https://conductscience.org/library/papers/35639288PubMed
1037564637Immunotherapies in MuSK-positive Myasthenia Gravis; an IgG4 antibody-mediated disease.Front Immunol2023https://conductscience.org/library/papers/37564637PubMed
1133662696Low-dose rituximab treatment for new-onset generalized myasthenia gravis.J Neuroimmunol2021https://conductscience.org/library/papers/33662696PubMed
1237388903Treatment of eculizumab refractory paroxysmal nocturnal hemoglobinuria: A systematic review about current treatment options and future direction.SAGE Open Med2023https://conductscience.org/library/papers/37388903PubMed
1335243555Individualized regimen of low-dose rituximab monotherapy for new-onset AChR-positive generalized myasthenia gravis.J Neurol2022https://conductscience.org/library/papers/35243555PubMed
1439624955Persistent symptoms, exacerbations and drug side effects despite treatment in myasthenia gravis.Eur J Neurol2025https://conductscience.org/library/papers/39624955PubMed
1531594658Risk factors associated with myasthenia gravis in thymoma patients: The potential role of thymic germinal centers.J Autoimmun2020https://conductscience.org/library/papers/31594658PubMed
1625745635Characterization of B cells in muscle-specific kinase antibody myasthenia gravis.Neurol Neuroimmunol Neuroinflamm2015https://conductscience.org/library/papers/25745635PubMed
1738152089Guideline for the management of myasthenic syndromes.Ther Adv Neurol Disord2023https://conductscience.org/library/papers/38152089PubMed
1837996128CAR T cells for treating autoimmune diseases.RMD Open2023https://conductscience.org/library/papers/37996128PubMed
1938711503B-cell immune dysregulation with low soluble CD22 levels in refractory seronegative myasthenia gravis.Front Immunol2024https://conductscience.org/library/papers/38711503PubMed
2015848049Myasthenia gravis patients with low plasma IL-6 and IFN-gamma benefit from etanercept treatment.J Autoimmun2005https://conductscience.org/library/papers/15848049PubMed

See all 170 referencesDownload CSV of references

Cited by5

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.

PMIDTitleJournalYearIn PapersSource
42776983Identification of rs28362336 as a risk SNP for generalized myasthenia gravis and its impact on HCG27 regulation.PLoS One2026https://conductscience.org/library/papers/42776983PubMed
42694599The immune microenvironment and population heterogeneity in myasthenia gravis: implications for precision therapeutics.Front Immunol2026https://conductscience.org/library/papers/42694599PubMed
42598382Assessing efgartigimod dosing patterns and Myasthenia Gravis Activities of Daily Living outcomes in clinical practice: results from a large patient support program database.Front Neurol2026https://conductscience.org/library/papers/42598382PubMed
42589271Precision Oncology in Thymic Epithelial Tumors: Therapeutic Horizons and Implementation Barriers.Int J Mol Sci2026https://conductscience.org/library/papers/42589271PubMed
41769309Emergency use of eculizumab in impending and manifest myasthenic crisis: a retrospective case series.Ther Adv Neurol Disord2026https://conductscience.org/library/papers/41769309PubMed

Download CSV of cited by

Genes8

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41008338

GET https://conductscience.org/api/papers/v1/41008338/references?page=2